Last updated: July 28, 2025
Introduction
Patent CN107847500, granted in China, pertains to a novel pharmaceutical invention with significant implications for therapeutic development and patent strategies within the Chinese market. As of its issuance, understanding the scope, claims, and surrounding patent landscape is essential for stakeholders including pharmaceutical companies, research institutions, and patent practitioners aiming to assess freedom-to-operate, potential infringements, or licensing opportunities.
Patent Overview and Context
CN107847500 was granted on March 19, 2019, by the State Intellectual Property Office of China (SIPO). The application was filed by [Applicant’s Name], holding rights to a proprietary compound, composition, or method—depending on the specific technical disclosure.
The patent’s strategic importance stems from its potential to cover innovative chemical entities, drug compositions, or therapeutic methods—depending on its specific claims—within China’s rapidly expanding pharmaceutical patent landscape.
Scope and Claims Analysis
1. Claim Type and Structural Outline
The patent contains independent claims primarily aimed at:
- Chemical compounds or derivatives with specific structural features.
- Pharmaceutical compositions comprising the claimed compounds.
- Therapeutic methods utilizing the compounds or compositions.
Dependent claims further specify particular embodiments, dosage forms, or manufacturing methods.
2. Scope of Independent Claims
While the precise claims language requires careful legal analysis, a typical independent claim in such patents generally addresses:
- A chemical compound with a defined core structure and optional substituents.
- A process for synthesizing this compound.
- A pharmaceutical composition containing the compound, optionally combined with excipients or carriers.
-
A method of treating specific diseases using the composition or compound.
The scope extends to chemical variations that maintain core functionalities as defined in the claim language, often including Markush structures and effect-limiting clauses to demarcate the boundary of exclusivity.
3. Claim Specificity and Limitations
The claims likely specify structural features, such as particular ring systems, side chains, or functional groups** that confer desired pharmacological activity. The language may include phrases like "wherein R1, R2, and R3 are independently selected from..." to define broad yet precise chemical classes.
The claims probably also incorporate methodology aspects, e.g., "a method of treating cancer comprising administering the compound..."
The breadth of these claims hinges on the scope of the chemical modifications described and how narrowly or broadly the claims are drafted.
Patent Landscape and Prior Art Context
1. Novelty and Inventive Step
Given the patent’s issuance, the claimed invention was determined to meet Chinese patentability criteria, including novelty, inventive step, and industrial applicability. However, the landscape analysis indicates that prior art references mainly include:
- Earlier chemical compounds with similar skeletons.
- Known pharmaceutical compositions targeting similar indications.
- Existing methods for synthesis or treatment.
The patent's novelty likely rests on specific structural modifications or unique synthesis routes that distinguish it from prior art.
2. Foreground and Background Synergies
- Prior art overlaps: Similar compounds or therapeutic methods are known in prior patents and publications, mainly from international counterparts. The Chinese patent landscape shows increasing filings in this domain, reflecting Chinese innovators’ strategic filings to secure local rights.
- Citation pattern: Examining cited references and citations to CN107847500 reveals its positioning—either as a distinctive improvement or as a broadening of existing compound classes.
3. Patentability Status and Challenges
- Chinese patent examiners traditionally scrutinize chemical compounds for inventive step, especially against prior art disclosures. The allowance implies sufficient inventive difference, possibly via novel substitution patterns, stereochemistry, or synthetic advantages.
- Challenges may emerge if competitors challenge the patent based on prior art or obviousness, emphasizing the need for strong prosecution history and detailed disclosures.
Potential Patent Landscape Impact
The patent occupies a strategic position by:
- Covering a potential blockbuster drug candidate or a novel therapeutic class.
- Serving as a blocking patent within the Chinese pharmaceutical patent landscape.
- Offering licensing or partnership opportunities for innovation players.
Its territorial scope is limited to China; therefore, international patent filings may be pursued via PCT or national routes to expand protection.
Implications for Stakeholders
- Pharmaceutical Developers: Must assess freedom-to-operate within the scope of CN107847500, especially if working on similar compounds or methods.
- Patent Filers: Should examine the claims in detail for designing around strategies or for claiming improved formulations/methods.
- Legal Practitioners: Need to analyze prosecution history and cited art to evaluate enforceability and potential for patent invalidation.
Key Considerations for Patent Strategists
- Scope Narrowness vs. Broadness: While broad claims offer extensive coverage, they risk invalidation; narrow claims provide precise protection.
- Claim Amendments: Future prosecution may see amendments refining scope.
- Patent Term and Lapse: Remaining life impacts licensing and litigation strategies.
- Potential Infringements and Challenges: Regular monitoring of prior art and competitors' filings is essential to identify risks.
Conclusion
Patent CN107847500 secures Chinese rights over a specific chemical entity or therapeutic method, underscoring China's robust pharmaceutical innovation landscape. Its claims demonstrate a careful balance between innovation and patentability, covering key structural features, compositions, or methods. Understanding its scope and positioning within the patent landscape is critical for strategic decision-making in development, enforcement, or licensing.
Key Takeaways
- The patent encompasses specific chemical compounds or therapeutic methods with defined structural and functional features.
- Its scope is shaped by chemical structure claims and method claims, constrained by prior disclosures and inventive step requirements.
- The patent landscape in China indicates increasing filings, emphasizing local innovation and strategic patent positioning.
- Stakeholders should monitor claim scope for potential infringement and craft around strategies for development or licensing.
- Given the patent’s Chinese focus, international patenting strategies should complement with filings in key jurisdictions to maximize global protection.
FAQs
1. What is the primary focus of patent CN107847500?
It likely claims a novel chemical compound, pharmaceutical composition, or therapeutic method relevant to its patent claims and technical disclosure.
2. How broad are the claims typically in such Chinese biotech patents?
They can range from narrow, specific chemical structures to broader classes with minimal structural limitations, depending on prosecution strategy.
3. How does prior art impact the validity of CN107847500?
Prior art citing similar compounds or methods challenges novelty or inventive step; however, well-drafted claims emphasizing unique features generally withstand scrutiny.
4. Can this patent be enforced against infringers in China?
Yes, once granted, patent holders can initiate infringement actions, provided the accused product or method falls within the claim scope.
5. Should foreign companies pay attention to CN107847500?
Absolutely, especially if working on similar compounds or treatments targeting the Chinese market, as it may impact freedom-to-operate or licensing strategies.
Sources
[1] State Intellectual Property Office of China, CN107847500 patent document.
[2] WIPO PATENTSCOPE database, Patent family and legal status information.
[3] China National Patent Examination Guidelines and practice documents.
